Organoids as preclinical platforms for metabolic dysfunction-associated steatotic liver disease: Model construction, mechanistic dissection, and therapeutic translation

doi:10.3748/wjg.123934

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 48

This Article

(4)

(2)

(0)

(57)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Dec 28, 2026; 32(48): 123934
Published online Dec 28, 2026. doi: 10.3748/wjg.123934

Full Size Figure Download Figure

Figure 3 Main key protective mechanisms against metabolic dysfunction-associated steatotic liver disease revealed in liver organoid studies. IL-22: Interleukin-22; IL-22RA1: Interleukin-22 receptor subunit alpha-1; UDPG: Uridine diphosphate glucose; S1P: Site-1 protease; SREBP: Sterol regulatory element-binding protein; 3β HCA: 3 beta-hydroxy-5-cholestenoic acid; DRP1: Dynamin-related protein 1; FAO: Fatty acid oxidation; ERK: Extracellular signal-regulated kinase; GDF15: Growth differentiation factor 15; TSP1: Thrombospondin 1; HSC: Hepatic stellate cell; ROS: Reactive oxygen species; HIF-1α: Hypoxia-inducible factor 1 alpha.

Citation: Xue HY, Ren TY, Pan Q, Fan JG. Organoids as preclinical platforms for metabolic dysfunction-associated steatotic liver disease: Model construction, mechanistic dissection, and therapeutic translation. World J Gastroenterol 2026; 32(48): 123934
URL: https://www.wjgnet.com/1007-9327/full/v32/i48/123934.htm
DOI: https://dx.doi.org/10.3748/wjg.123934

Xue HY, Ren TY, Pan Q, Fan JG. Organoids as preclinical platforms for metabolic dysfunction-associated steatotic liver disease: Model construction, mechanistic dissection, and therapeutic translation. World J Gastroenterol 2026; 32(48): 123934 [DOI: 10.3748/wjg.123934]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.